COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.73M | -1.42M | -1.40M | -1.40M | 7.43M |
| Total Depreciation and Amortization | 392.00K | 377.00K | 359.00K | 359.00K | 1.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.59M | -2.16M | -398.00K | -398.00K | -1.11M |
| Change in Net Operating Assets | 754.00K | 1.82M | -961.00K | -961.00K | 1.51M |
| Cash from Operations | -3.00M | -1.39M | -2.40M | -2.40M | 9.16M |
| Capital Expenditure | -309.00K | -157.00K | -564.00K | -564.00K | -708.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 26.04M | 0.00 | 0.00 | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.00K | -- | -- | -- | -7.00K |
| Cash from Investing | -316.00K | 25.88M | -564.00K | -564.00K | -715.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -109.00K | -126.00K | -72.00K | -72.00K | -257.00K |
| Issuance of Common Stock | -- | -- | -- | -- | 13.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -93.00K | -- | -- | -- | -- |
| Cash from Financing | -202.00K | -126.00K | -72.00K | -72.00K | -244.00K |
| Foreign Exchange rate Adjustments | -88.00K | -67.00K | -135.00K | -135.00K | 146.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.61M | 24.30M | -3.17M | -3.17M | 8.34M |